Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term tu. Found 4 abstracts

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. 2007 May 31;356(22):2271-81.
Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.[see comment]. Journal of Clinical Oncology. 2006 Sep;24(25):4069-77.
Gallo JM, Vicini P, Orlansky A, Li S, Zhou F, Ma J, Pulfer S, Bookman MA, Guo P. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clinical Cancer Research. 2004 Dec;10(23):8048-58.
Sasson AR, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol NJ, Freedman G, Pingpank JF, Eisenberg BL. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. International Journal of Gastrointestinal Cancer. 2003 Jan;34(2-3):121-8.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term tu

[Therapeutic Use] tu dt [Drug Therapy] aa [Analogs & Derivatives] Antineoplastic Combined Chemotherapy Protocols Female Male Middle Aged Adult ad [Administration & Dosage] Aged 80 and over Aged Survival Analysis pa [Pathology] me [Metabolism] Proportional Hazards Models 951-77-9 (Deoxycytidine) 0 (Antineoplastic Combined Chemotherapy Protocols) Predictive Value of Tests Fluorouracil 51-21-8 (Fluorouracil) Deoxycytidine sc [Secondary] 0 (cci 779) Effects] 53123-88-9 (Sirolimus) Carboplatin Topotecan rt [Radiotherapy] 85622-93-1 (temozolomide) Biological Models en [Enzymology] 50-07-7 (Mitomycin) Sesquiterpenes Fibrosis et [Etiology] Hematologic Diseases Reverse Transcriptase Polymerase Chain Reaction Dihydrouracil Dehydrogenase (NADP) EC 2-7-1-37 (Protein Kinases) Computer Simulation pk Treatment Outcome ae [Adverse EC 2-1-1-45 (Thymidylate Synthase) 41575-94-4 (Carboplatin) Interferon-alpha mo [Mortality] Vascular Endothelial Growth Factor A 123948-87-8 (Topotecan) su [Surgery] Feasibility Studies EC 1-3-1-2 (Dihydrouracil Dehydrogenase (NADP)) Rats Brain Neoplasms 0 (Vascular Endothelial Growth Factor A) Neoplastic Gene Expression Regulation Adenocarcinoma EC 2-7-1 (mTOR protein) Neoadjuvant Therapy 103882-84-4 (gemcitabine) Renal Cell Carcinoma ci [Chemically Induced] Thymidine Phosphorylase 0 (Sesquiterpenes) Retrospective Studies Kidney Neoplasms Enzymologic Gene Expression Regulation Protein Kinases Heterologous Transplantation Colorectal Neoplasms Prognosis 7689-03-4 (Camptothecin) 0 (Interferon-alpha) Antineoplastic Agents Ovarian Neoplasms 154361-50-9 (capecitabine) Protein Kinase Inhibitors EC 2-4-2-4 (Thymidine Phosphorylase) Biological) 0 (Tumor Markers Thymidylate Synthase 129298-91-5 (O-(chloroacetylcarbamoyl)fumagillol) Sirolimus Camptothecin Mitomycin Biological Tumor Markers Disease-Free Survival 4342-03-4 (Dacarbazine) Non-US Gov't Research Support Inbred F344 Rats 0 (Protein Kinase Inhibitors) 0 (Antineoplastic Agents) Neoplasm Staging human) 0 (vascular endothelial growth factor A 100286-90-6 (irinotecan) [Pharmacokinetics] ae [Adverse Effects] Nude Rats Pancreatectomy tu [Therapeutic Use] Immunohistochemistry Logistic Models Dacarbazine Pancreatic Neoplasms
Last updated on Wednesday, February 05, 2020